182,534 Moderna, Inc. $MRNA Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 13.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,160,945 shares of the company’s stock after selling 182,534 shares during the period. Moderna accounts for 2.7% of Douglas Lane & Associates LLC’s holdings, making the stock its 5th biggest holding. Douglas Lane & Associates LLC’s holdings in Moderna were worth $223,563,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. TD Waterhouse Canada Inc. boosted its position in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after purchasing an additional 85 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Moderna by 8.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 1,976 shares of the company’s stock valued at $381,000 after purchasing an additional 159 shares in the last quarter. Assetmark Inc. boosted its holdings in Moderna by 35.1% during the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after acquiring an additional 208 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Moderna by 13.8% during the 3rd quarter. Versant Capital Management Inc now owns 2,491 shares of the company’s stock worth $480,000 after buying an additional 302 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Moderna by 21.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 387 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 118,882 shares of company stock valued at $16,862,280. Corporate insiders own 10.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Singular Research upgraded Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research note on Friday, August 28th. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research note on Friday, August 28th. They set a “hold” rating on the stock. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $78.17.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Nasdaq-100 reentry may drive additional demand. Moderna is scheduled to rejoin the Nasdaq-100 before the October 9 market open, replacing Warner Bros. Discovery. The inclusion follows a substantial rise in Moderna’s market capitalization and could prompt buying by index-tracking funds, providing a near-term technical tailwind. Moderna’s Nasdaq-100 Entry: What Does It Mean for the Stock?
• Positive Sentiment: Investors are increasingly focused on Moderna’s cancer opportunity. Moderna and Merck are expanding development of the individualized neoantigen therapy intismeran autogene, also known as V940 or mRNA-4157, including studies in melanoma and other cancers. The collaboration with Tempus is intended to support potential commercialization and strengthens the long-term oncology narrative. Tempus Announces Multi-Year Collaboration with Moderna and Merck
• Positive Sentiment: Manufacturing capabilities are becoming a key part of the bull case. Recent coverage highlights Moderna’s efforts to apply lessons from its COVID-era production network to manufacture future cancer therapies at commercial scale. Successful execution could improve confidence in the company’s ability to convert its pipeline into revenue. Moderna’s Next Test: Manufacturing a Cancer Franchise at Scale
• Neutral Sentiment: Analyst sentiment remains cautious. Morgan Stanley reportedly assigned Moderna a “Hold” rating, suggesting that the recent rally may already reflect substantial optimism about the oncology pipeline and index inclusion. Moderna Gets a Hold from Morgan Stanley
• Negative Sentiment: Execution and valuation risks are rising after the surge. Commentary emphasizes that scaling cancer manufacturing will be a major test, while reports that insiders are trimming holdings could add to concerns that the stock has moved ahead of near-term fundamentals. Moderna Builds the Back Office for a Cancer Franchise as Insiders Trim Holdings

Moderna Stock Up 11.2%

NASDAQ MRNA traded up $22.04 during midday trading on Friday, hitting $219.03. 17,695,772 shares of the company traded hands, compared to its average volume of 12,174,882. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The company has a market cap of $87.45 billion, a PE ratio of -27.44 and a beta of 1.09. The company’s 50-day simple moving average is $136.67 and its 200-day simple moving average is $83.94. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $219.31.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the firm posted ($2.13) earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, equities research analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.